<?xml version="1.0" encoding="UTF-8"?>
<p>Decreased hemoglobin for autoimmune hemolytic anemia can be managed with a course of corticosteroids and it is not an indication for anti-CLL treatment. Corticosteroids have the largest evidence of activity in CLL-related autoimmune hemolytic anemia and are the guidelines-recommended first line treatment.
 <sup>
  <xref rid="R34" ref-type="bibr">34</xref>
 </sup> It is not known whether corticosteroids increases the risk of SARS-CoV-2 infection or mitigates its severity.
 <sup>
  <xref rid="R29" ref-type="bibr">29</xref>,
  <xref rid="R64" ref-type="bibr">64</xref>–
  <xref rid="R70" ref-type="bibr">70</xref>
 </sup> Clinical trials with novel agents excluded patients with uncontrolled autoimmune hemolytic anemia.
 <sup>
  <xref rid="R43" ref-type="bibr">43</xref>–
  <xref rid="R46" ref-type="bibr">46</xref>,
  <xref rid="R54" ref-type="bibr">54</xref>,
  <xref rid="R56" ref-type="bibr">56</xref>,
  <xref rid="R58" ref-type="bibr">58</xref>,
  <xref rid="R59" ref-type="bibr">59</xref>
 </sup> However, treatment with BTK inhibitors facilitate withdrawal of ongoing immune suppressive agents in controlling hemolytic manifestations.
 <sup>
  <xref rid="R71" ref-type="bibr">71</xref>
 </sup>
</p>
